MD Anderson Cancer Center and Guardant Health announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment.
Indivumed, GmbH and Regeneron Pharmaceuticals Inc. signed an agreement providing Regeneron with access to Indivumed's quality tissue sample and clinical and molecular data collection methods, to support the company's cancer research programs.
The Addario Lung Cancer Medical Institute, the Bonnie J. Addario Lung Cancer Foundation and Scancell Holdings PLC announced a collaboration to evaluate the use of Scancell's second innovative cancer vaccine, SCIB2, from its ImmunoBody platform to treat non-small cell lung cancer.
Perthera Inc. said Novartis will use Perthera's cancer patient network to identify breast and lung cancer patients for targeted therapy trials.
Benitec Biopharma Ltd. started work on two oncology pipeline programs after executing a research collaboration agreement with Nant Capital LLC.
GenomeDx Biosciences entered into a research collaboration with Astellas to apply genomic tumor profiling using GenomeDx's Decipher Classifier and Decipher GRID as a potential aid in the identification of prostate cancer patients undergoing active surveillance who may benefit from treatment with XTANDI (enzalutamide).
FDA approved the drug Imbruvica (imbrutinib) for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Merck KGaA, Darmstadt, Germany, announced a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
Genentech said FDA accepted the company's supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated or have disease progression at least 12 months after receiving chemotherapy before surgery or after surgery.
ONCURIOUS NV, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, announced that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma.
